This work shows that activation of the integrated stress response (ISR) with orally available and clinically approved GCN2 activator halofuginone reduces diabetes-like phenotypes in a mouse model of diet-induced obesity. The gene discussed is EIF2AK4; the disease is diabetes mellitus.